REGENXBIO Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
REGENXBIO Inc. (RGNX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$37.09 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- REGENXBIO Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$37.09M, a 1272.49% decline year-over-year.
- REGENXBIO Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$1.14M, a 106.64% decline year-over-year.
- REGENXBIO Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $18.77M, a 91.50% increase year-over-year.
- REGENXBIO Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$25.57M, a 984.03% decline year-over-year.
- REGENXBIO Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$4.79M, a 125.00% decline from fiscal 2016.
- REGENXBIO Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $19.16M.
- REGENXBIO Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$163.80M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$37.09M 10-Q · filed 2018-05-08 | -$38.23M derived: sum of 2 quarters · filed 2018-05-08 | -$19.46M derived: sum of 3 quarters · filed 2018-05-08 | -$45.04M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $17.62M derived: sum of 2 quarters · filed 2018-03-06 | -$7.95M derived: sum of 3 quarters · filed 2018-03-06 | -$4.79M 10-K · filed 2018-03-06 |
| 2017-09-30 | $18.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$6.81M derived: sum of 2 quarters · filed 2017-11-08 | -$3.65M 10-Q · filed 2017-11-08 | $13.56M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | -$25.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$22.41M 10-Q · filed 2017-08-08 | -$5.20M derived: sum of 3 quarters · filed 2018-05-08 | $4.60M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | $3.16M 10-Q · filed 2018-05-08 | $20.37M derived: sum of 2 quarters · filed 2018-05-08 | $30.17M derived: sum of 3 quarters · filed 2018-05-08 | $33.06M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $17.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $27.01M derived: sum of 2 quarters · filed 2018-03-06 | $29.90M derived: sum of 3 quarters · filed 2018-03-06 | $19.16M 10-K · filed 2018-03-06 |
| 2016-09-30 | $9.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $12.69M derived: sum of 2 quarters · filed 2017-11-08 | $1.95M 10-Q · filed 2017-11-08 | -$142.39M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-06-30 | $2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$7.85M 10-Q · filed 2017-08-08 | -$152.19M derived: sum of 3 quarters · filed 2018-03-06 | -$171.33M derived: sum of 4 quarters · filed 2018-03-06 |
| 2016-03-31 | -$10.74M 10-Q · filed 2017-05-09 | -$155.08M derived: sum of 2 quarters · filed 2018-03-06 | -$174.22M derived: sum of 3 quarters · filed 2018-03-06 | -$174.43M derived: sum of 4 quarters · filed 2018-03-06 |
| 2015-12-31 | -$144.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | -$163.49M derived: sum of 2 quarters · filed 2018-03-06 | -$163.69M derived: sum of 3 quarters · filed 2018-03-06 | -$163.80M 10-K · filed 2018-03-06 |
| 2015-09-30 | -$19.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$19.35M derived: sum of 2 quarters · filed 2016-11-09 | -$19.46M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$315.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | -$106.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |